Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial

American Heart Journal

Volumn 196, Issue , 2018, Pages 105-112

  Vranckx, Pascal ^a   Lewalter, Thorsten ^b   Valgimigli, Marco ^c   Tijssen, Jan G ^d   Reimitz, Paul Egbert ^e   Eckardt, Lars ^f   Lanz, Hans Joachim ^e   Zierhut, Wolfgang ^e   Smolnik, Rüdiger ^e   Goette, Andreas ^g  

^a HASSELT UNIVERSITY   (Belgium)

^b Hospital Munich Thalkirchen   (Germany)

^c BERN UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e DAIICHI SANKYO CO   (Japan)

^f UNIVERSITY OF MÜNSTER   (Germany)

^g UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; CLOPIDOGREL; EDOXABAN; PRASUGREL; TICAGRELOR; FIBRINOLYTIC AGENT; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DUAL ANTIPLATELET THERAPY; HEART INFARCTION; HUMAN; HYPERTENSION; INTENTION TO TREAT ANALYSIS; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; PERCUTANEOUS CORONARY INTERVENTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STENT THROMBOSIS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; FEMALE; INTERNATIONAL COOPERATION; MALE; MORTALITY; ORAL DRUG ADMINISTRATION; PATIENT SAFETY; POSTOPERATIVE COMPLICATION; PROCEDURES; RISK ASSESSMENT; SINGLE BLIND PROCEDURE; STENT; SURVIVAL RATE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ATRIAL FIBRILLATION; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INTERNATIONALITY; MALE; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE COMPLICATIONS; PYRIDINES; RISK ASSESSMENT; SINGLE-BLIND METHOD; STENTS; SURVIVAL RATE; THIAZOLES; TREATMENT OUTCOME;

EID: 85036548236     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2017.10.009     Document Type: Article

References (25)

1. Lip, G.Y., Windecker, S., Huber, K., et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 35:45 (2014), 3155–3179.
2. Windecker, S., Kolh, P., Alfonso, F., et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35:37 (2014), 2541–2619.
3. Levine, G.N., Bates, E.R., Blankenship, J.C., et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 58:24 (2011), e44–e122.
4. Rubboli, A., Colletta, M., Valencia, J., et al. Periprocedural management and in-hospital outcome of patients with indication for oral anticoagulation undergoing coronary artery stenting. J Interv Cardiol 22:4 (2009), 390–397.
5. Heidbuchel, H., Verhamme, P., Alings, M., et al. Updated European Heart Rhythm Association practical guide on the use of non–vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 17:10 (2015), 1467–1507.
6. You, J.J., Singer, D.E., Howard, P.A., et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:2 Suppl (2012), e531S–e575S.
7. Moser, M., Olivier, C.B., Bode, C., Triple antithrombotic therapy in cardiac patients: more questions than answers. Eur Heart J 35:4 (2014), 216–223.
8. Faxon, D.P., Eikelboom, J.W., Berger, P.B., et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 106:4 (2011), 572–584.
9. January, C.T., Wann, L.S., Alpert, J.S., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 130:23 (2014), 2071–2104.
10. Anderson, J.L., Halperin, J.L., Albert, N.M., et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61:18 (2013), 1935–1944.
11. Hansen, M.L., Sorensen, R., Clausen, M.T., et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 170:16 (2010), 1433–1441.
12. Kirchhof, P., Benussi, S., Kotecha, D., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:38 (2016), 2893–2962.
13. Dewilde, W.J., Oirbans, T., Verheugt, F.W., et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 381:9872 (2013), 1107–1115.
14. Lamberts, M., Olesen, J.B., Ruwald, M.H., et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation 126:10 (2012), 1185–1193.
15. Goette, A., Kalman, J.M., Aguinaga, L., et al. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Europace 18:10 (2016), 1455–1490.
16. Camm, A.J., Lip, G.Y., De Caterina, R., et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33:21 (2012), 2719–2747.
17. Gibson, C.M., Mehran, R., Bode, C., et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med, 2016, 10.1177/1076029617710334 [Epub ahead of print].
18. Cannon, C.P., Bhatt, D.L., Oldgren, J., et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 377:16 (2017), 1513–1524.
19. Goette, A., Merino, J.L., Ezekowitz, M.D., et al. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet 388:10055 (2016), 1995–2003.
20. Giugliano, R.P., Ruff, C.T., Braunwald, E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:22 (2013), 2093–2104.
21. Mehran, R., Rao, S.V., Bhatt, D.L., et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123:23 (2011), 2736–2747.
22. Schulman, S., Kearon, C., Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:4 (2005), 692–694.
23. Bovill, E.G., Terrin, M.L., Stump, D.C., et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), phase II trial. Ann Intern Med 115:4 (1991), 256–265.
24. Wiviott, S.D., Braunwald, E., McCabe, C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:20 (2007), 2001–2015.
25. Buller, H.R., Decousus, H., Grosso, M.A., et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369:15 (2013), 1406–1415.